User:Wuadrc/John C Morris

John C. Morris, MD is the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology, Professor of Pathology and Immunology, Professor of Physical Therapy, and Professor of Occupational Therapy at Washington University. He also is the Director and Principal Investigator of the Alzheimer's Disease Research Center.

Dr. Morris is the Principal Investigator of two program projects, "Healthy Aging and Senile Dementia," and "Antecedent Biomarkers for AD: The Adult Children Study" and the center grant, "Alzheimer Disease Research Center," all funded by the National Institute on Aging (NIA). He also is Principal Investigator for the NIA-funded Consortium for the "Dominantly Inherited Alzheimer's Network". He directs Washington University's Harvey A. Friedman Center for Aging. In the Medical School's Department of Neurology, Dr. Morris serves as Head of the Dementia and Aging Section.

Dr. Morris is a member of the Alzheimer's Association's Medical & Scientific Advisory Committee. He chairs the Clinical Task Force for the NIA's Alzheimer Disease Centers program. He is author or co-author of over300 peer-reviewed journal articles and 50 chapters and reviews. He edited the the first and second editions of the Handbook of Dementing Illnesses. He has received many honors, including the Distinguished Achievement Citation from his alma mater, Ohio Wesleyan University (2000), the Lifetime Achievement Award from the Alzheimer's Association (2004), the 2004 MetLife Foundation Award for Medical Research, the 2005 Potamkin Prize for Research in Pick's, Alzheimer's, and Related Disease from the American Academy of Neurology and the Physician-Scientist Lifetime Achievement Award (2005) and the 2006 Dr. Neville Grant Award for Clinical Excellence from the Barnes-Jewish Hospital Foundation (St. Louis, Missouri). In 2008, he received the 2008 Washington University Academic Women's Network Mentor Award.

The focus of Dr. Morris' research and practice is Alzheimer's disease and other neurological disorders associated with aging. Specific research interests include detecting preclinical Alzheimer's disease, improving the diagnosis of early-stage Alzheimer's disease, evaluating new drugs for the treatment of dementia, and establishing phenotypes for inherited forms of Alzheimer's disease and other dementias.

Medical Training

Dr. Morris received his B.A. from Ohio Wesleyan University. After receiving his MD from the University of Rochester School of Medicine and Dentistry in Rochester, NY, in 1974, he completed his internship at San Francisco General Hospital before joining a private practice as a family physician in Fairbanks, Alaska (1975-76) and then directing the Emergency Room at Carlsbad Regional Medical Center in New Mexico (1976-77). Dr. Morris received board certification in Internal Medicine and Neurology after returning to Ohio to complete residency programs in medicine (Akron General Medical Center) and neurology (Cleveland Metropolitan General Hospital). He joined Washington University School of Medicine in 1982 as a postdoctoral fellow in neuropharmacology and as an Instructor in Neurology in 1983. Dr. Morris was named as the Harvey A. and Dorismae Hacker Friedman Professor of Neurology in 1998 and Distinguished Professor in 2003.

Selected Publications

Galvin JE, Meuser TM, Coats MA, Bakal DA, Morris JC. The "Portable" CDR: Translating the clinical dementia rating interview into a PDA format. Alzheimer Dis Assoc Disord 2009; 23:44-49.

Rapoport MJ, Herrmann N, Molnar F, Rochon PA, Juurlink DN, Zagorski B, Seitz D, Morris JC, Redelmeier DA. Psychotropic medications and motor vehicle collisions in patients with dementia. JAGS 2008; 56:1968-1970.

Dickerson BC, Bakkour A, Salat D, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL. The cortical signature of Alzheimer's disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cerebral Cortex 2009; 19:497.510.

Dickerson BC, Feczko E, Augusinack JC, Pacheco J, Morris JC, Fischl B, Buckner RL. Differential effects of aging and Alzheimer's disease on medial temporal lobe neocortical thickness and surface area. Neurobiol. Aging 2009; 30:432-440.

Kauwe JSK, Wang J, Mayo K, Morris JC, Fagan AM, Holtzman DM, Goate AM. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics 2009; 10:13-17.

Fagan AM, Head, D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009; 65:176-183.

Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: Regional thinning predicts mild AD dementia. Neurology 2009; 72:1048-1055.

Wilkins CH, Birge SJ, Sheline YI, Morris JC. Vitamin D deficiency is associated with worse cognitive performance and lower bone density in older African Americans. J. Natl Med Assoc 2009;101:349-354.

Andrieu S, Coley N, Aisen P, Carrillo M, DeKosky S, Durga J, Fillit H, Frisoni G, Froelich L, Gauthier S, Jones R, Jonsson L, Khachaturian Z, Morris JC, Orgogozo J-M, Ousset P-J, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. Methodological issues in primary prevention trials for neurodegenerative dementia. J. Alz Dis 2009; 16:235-270.

Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026-1036.

Wilkins CH, Roe CM, Morris JC. A brief clinical tool to assess physical function: The mini-physical performance test. Arch.Gerontol.Geriatr. 2009;(doi:10.1016/j.archger.2009.02.2006)

Schneider L, Raman R, Schmitt FA, Doody R, Insel P, Clark CM, Morris JC, Reisberg B, Petersen RC, Ferris SH. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC + for Mild Cognitive Impairment clinical Trials. Alz Dis Assoc Disorders 2009; 23:260-267.

Malmstrom TK, Miller DK, Coats MA, Jackson, Miller JP, Morris JC. Informant based dementia screening in a population-based sample of African Americans. Alzheimer Dis Assoc Dis 2009; 23:117-123.

Wang L, Khan A, Csernansky JG, Fischl B, Miller MI, Morris JC, Beg MF. Fully-automated, multi-stage hippocampus mapping in very mild Alzheimer Disease. Hippocampus, June 2009;19:541-548.

Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford N, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D, Peskind E, Dietrich W, Beekly DL, Kukull B, Morris JC. The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychological Test Battery. Alzheimer Dis Assoc Dis 2009; 23:91-101.

Williams MM, Roe CM, Morris JC. Stability of the Clinical Dementia Rating: 1979-2007. Archives of Neurology 2009; 66:773-777.

Snider BJ, Fagan AM, Roe CM, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM. CSF biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Archives of Neurology 2009; 66:638-645.

Stark S, Landsbaum A, Palmer JL, Somerville EK, Morris JC. Client-centred home modifications improve daily activity performance of older adults. Can J of Occup Ther 2009;76:235-245.

Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 2009. doi:10.1016/j.biopsych.2009.08.024.

Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to AD. Arch Neurology 2009; 66:1254-1259.

Ghoshal N, Cali I, Perrin RJ, Josephson SA, Sun N, Gambetti P, Morris JC. Co-distribution of Amyloid plaques and spongiform degeneration in familial Creutzfeldt-Jakob disease with the E200K-129M Haplotype. Archives of Neurology 2009; 66:1240-1246.

Avidan MS, Searleman AC, Storandt M, Barnett K, Vannucci A, Saager L, Xiong C, Grant EA, Kaiser D, Morris JC, Evers AS. Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness. Anesthesiology 2009; 111:963-9.

Cairns NJ, Ikonomovic, MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Taylor-Reinwald L, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh Compound B detection of cerebral amyloid β in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer's Disease. Archives of Neurology 2009; 66:1557-1562.

Morris JC; Roe CM; Grant EA; Head D; Storandt M; Goate AM; Fagan AM; Holtzman DM;Mintun MA. Pittsburgh Compound B Imaging and Prediction of Progression from Cognitive Normality to Symptomatic Alzheimer's Disease. Archives Neurology 2009; 66:1469-1475.

Storandt M, Mintun M, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral Amyloid-β peptide deposition identified with Pittsburgh Compound B. Archives of Neurology 2009; 66:1476-1481.

Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau181 increase with coritical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009,1:371-380.

Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere M, Pahwa JS, Moskvina V, DowzellK, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Ribinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, DeDeyn P, van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel K-H, Klopp N, Wichmann H-E, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics 2009; doi:10.1038/ngXXXX.

Gitcho MA, Bigio EH, Mishra M, Johnson N, Weintraub S, Mesulam M, Rademakers R, Chakraverty S, Cruchaga C, Morris JC, Goate AM, Cairns NJ. TARDB 3'UTR mutation in autopsy-confirmed frontotemporallobar degenerationwithTDP-43 proteinopathy. Acta Neuropathologica 2009; 118:633-645.